Overview
New Horizons in Pustular Psoriasis: Will You Be Ready?
CME Virtual Meet-Up’s Highlights
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Clinicians must be ready to translate the latest guidance and emerging science on pustular psoriasis to improve outcomes for their dermatology patients. Leading expert, Dr. Mark Lebwohl from the Icahn School of Medicine at Mount Sinai recently hosted several small group CME Meet-Ups. This recorded Meet-Up discusses:
• the lack of U.S. guidance that complicates diagnosis and disease assessment
• the most recent pathophysiologic findings for pustular psoriasis and implications for treatment
• the latest safety and efficacy data for new and emerging agents for pustular psoriasis
• the lack of U.S. guidance that complicates diagnosis and disease assessment
• the most recent pathophysiologic findings for pustular psoriasis and implications for treatment
• the latest safety and efficacy data for new and emerging agents for pustular psoriasis
This activity is intended for dermatologists, primary care providers, nurse practitioners, and physician assistants who treat patients with pustular psoriasis.
In the absence of recent US guidelines, dermatologists managing the various pustular psoriasis subtypes are faced with a multitude of challenges across diagnosis, severity assessment, and management. In addition, dermatologists must keep abreast of novel targeted therapies in development, based on newer data on the specific genetic causes of pustular psoriasis. This activity will review the latest in pustular psoriasis diagnosis, assessment, and management to help overcome the present diagnostic and treatment challenges and to help dermatologists best care for their patients. This program will also better prepare clinicians to incorporate novel pustular psoriasis therapies into practice once these agents become approved.
Upon completion of this activity, participants will be able to:
• Assess patients with pustular psoriasis, based on clinical manifestations, diagnostic criteria, and disease severity.
• Discuss the pathophysiology of pustular psoriasis, including how it differs from that of plaque psoriasis and potential pathways for therapeutic targets.
• Review the clinical profiles and mechanisms of action of new and emerging biologic treatment options for adults with PPP and GPP.
• Assess patients with pustular psoriasis, based on clinical manifestations, diagnostic criteria, and disease severity.
• Discuss the pathophysiology of pustular psoriasis, including how it differs from that of plaque psoriasis and potential pathways for therapeutic targets.
• Review the clinical profiles and mechanisms of action of new and emerging biologic treatment options for adults with PPP and GPP.
• Pustular Psoriasis Epidemiology and Assessing Disease Severity
• Advances in Pathophysiological Findings in Pustular Psoriasis
• New and Emerging Therapies for Pustular Psoriasis
• Therapy Selection and Future Directions
• Advances in Pathophysiological Findings in Pustular Psoriasis
• New and Emerging Therapies for Pustular Psoriasis
• Therapy Selection and Future Directions
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Dean for Clinical Therapeutics
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires the faculty participating in an accredited continuing education activity to disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Mark Lebwohl, MD, (Chair)
Consultant: Aditum Bio, Almirall, AnaptysBio, Arcutis Biotherapeutics, Aristea Therapeutics, Arrive Technologies, Inc., Avotres Therapeutics LLC, BiomX Inc., Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, LLC, Dermavant Sciences, Dr. Reddy's Laboratories Ltd., Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences Inc., Foundation for Research and Education in Dermatology, Helsinn Therapeutics, LEO Pharma Inc., Meiji Seika Pharma Co., Ltd., Mindera Consultant, Pfizer Inc., Verrica Pharmaceuticals
Research Funds: Abbvie, Amgen, Arcutis Biotherapeutics, Avotres Inc., Boehringer Ingelheim, Dermavant Sciences, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Inc., Regeneron Pharmaceuticals, UCB
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: systemic corticosteroids, acitretin, cyclosporine A, methotrexate, infliximab, adalimumab, etanercept, psoralen plus ultraviolet A, aprelimast, certolizumab pegol, ustekinumab, guselkumab, secukinumab, ixekizumab, brodalumab, isotretinoin for pustular psoriasis. Discussion of investigational spesolimab and imsidolimab for pustular psoriasis.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
